Mitochondrial DNA ( mtDNA ) as fluid biomarker in neurodegenerative disorders: A systematic review
European Journal of Neurology · 2025
DOI: 10.1111/ene.70014 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Barbara Risi und 5 weiteren Autor:innen. Beteiligte Einrichtung: NeMO-Brescia Clinical Center for Neuromuscular Diseases, Brescia, Italy. Hauptthemen laut MEDLINE: DNA, Mitochondrial, Neurodegenerative Diseases. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Several studies evaluated peripheral and cerebrospinal fluid (CSF) mtDNA as a putative biomarker in neurodegenerative diseases, often yielding inconsistent findings. We systematically reviewed the current evidence assessing blood and CSF mtDNA levels and variant burden in Parkinson's disease (PD), Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). Multiple sclerosis (MS) was also included as a paradigm of chronic neuroinflammation‐driven neurodegeneration.
Methods
Medline, Embase, Scopus and Web of Science were searched for articles published from inception until October 2023. Studies focused on mtDNA haplogroups or hereditary pathogenic variants were excluded. Critical appraisal was performed using the Quality Assessment for Diagnostic Accuracy Studies criteria.
Results
Fifty‐nine original studies met our a priori‐defined inclusion criteria. The majority of CSF‐focused studies showed (i) decreased mtDNA levels in PD and AD; (ii) increased levels in MS compared to controls. No studies evaluated CSF mtDNA in ALS. Results focused on blood cell‐free and intracellular mtDNA were contradictory, even within studies evaluating the same disease. This poor reproducibility is likely due to the lack of consideration of the many factors known to affect mtDNA levels. mtDNA damage and methylation levels were increased and reduced in patients compared to controls, respectively. A few studies investigated the correlation between mtDNA and disease severity, with conflicting results.
Conclusions
Additional well‐designed studies are needed to evaluate CSF and blood mtDNA profiles as putative biomarkers in neurodegenerative diseases. The identification of “mitochondrial subtypes” of disease may enable novel precision medicine strategies to counteract neurodegeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NeMO-Brescia Clinical Center for Neuromuscular Diseases, Brescia, Italy.
- Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
- Department of Molecular Medicine, University of Pavia, Pavia, Italy.
- Neurogenetics Research Centre, IRCCS Mondino Foundation, Pavia, Italy.
- Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
- Unit of Neurology, ASST Spedali Civili, Brescia, Italy.
ORCID-Profile: Barbara Risi, Alberto Imarisio, Massimiliano Filosto
Zitieren
APA
Risi, B., Imarisio, A., Cuconato, G., Padovani, A., Valente, E. M., & Filosto, M. (2025). Mitochondrial DNA ( mtDNA ) as fluid biomarker in neurodegenerative disorders: A systematic review. European Journal of Neurology. https://doi.org/10.1111/ene.70014
Vancouver
Risi B, Imarisio A, Cuconato G, Padovani A, Valente EM, Filosto M. Mitochondrial DNA ( mtDNA ) as fluid biomarker in neurodegenerative disorders: A systematic review. European Journal of Neurology. 2025. doi:10.1111/ene.70014
BibTeX
@article{Risi2025,
author = {Risi, Barbara and Imarisio, Alberto and Cuconato, Giada and Padovani, Alessandro and Valente, Enza Maria and Filosto, Massimiliano},
title = {Mitochondrial DNA ( mtDNA ) as fluid biomarker in neurodegenerative disorders: A systematic review},
journal = {European Journal of Neurology},
year = {2025},
doi = {10.1111/ene.70014}
}
EUVIMED